[Featured Stock] iBeamTech, World's First Technology Recognized by Harvard and Sanofi... Reverses to Rise in the Afternoon

World's First All-in-One Biomicroscope...Supplied to Harvard University, Johns Hopkins University, Sanofi, etc.
Securing New Growth Engine by Entering AI Diagnostic Medical Device Business
Focused Investment in R&D, Overseas Expansion, and Facility Expansion

iBeam Technology is expanding its gains in the afternoon session.

On the 6th, iBeam Technology, which was listed on the KOSDAQ market at a public offering price of 10,000 KRW, started trading at 10,000 KRW. Around 10:49 AM, the price dropped to 8,560 KRW but reversed to an upward trend in the afternoon. At 1:53 PM that day, iBeam Technology was trading at 13,580 KRW, up 35.8% from the public offering price.

Founded in 2017, iBeam Technology succeeded in commercializing the world's first all-in-one integrated bio-microscope equipment. CEO Kim Pilhan, who is a professor at the Korea Advanced Institute of Science and Technology (KAIST) Graduate School of Medical Science, developed the core technology for bio-microscopy (IVM).

iBeam Technology's flagship product, the 'bio-microscope,' is an advanced laser optical microscope device that allows direct observation of the fine structures inside living organisms. It offers real-time imaging and 3D visualization of various cells, proteins, and drugs at a resolution 100 times higher than magnetic resonance imaging (MRI). This enables direct tracking and analysis of target cells and drug movements within the microenvironment of living organisms, surpassing the limitations of existing imaging technologies.

This product features an all-in-one system optimized integrally by combining ▲ real-time bio-imaging technology through ultra-high-speed laser scanning ▲ continuous maintenance of bio-survival and homeostasis during long-term imaging ▲ high-performance bio-motion correction software and algorithms.

In the domestic market, it is supplied to various research institutions starting with Seoul National University College of Medicine, the top research institution. In overseas markets, sales channels have expanded to include top U.S. research institutions such as Harvard University, Johns Hopkins University, and the University of Massachusetts, followed by Sanofi, a global top 10 pharmaceutical company. It has also been installed at the University of Oxford in the UK, the Max Planck Institute in Germany, the Spanish National Cancer Research Center, and Wuhan University in China, where collaborative research has been conducted.

iBeam Technology is developing medical devices that integrate artificial intelligence (AI) technology to provide immediate tissue diagnostic and analysis imaging information at medical sites, equivalent to various tissue biopsy levels currently conducted in clinical settings, using only its bio-microscope equipment without separate pathology facilities.

The funds raised through the initial public offering (IPO) will be used for operating capital, research and development, overseas expansion, and facility expansion. They will be invested in advancing the core bio-microscope technology, developing new products, and researching and commercializing AI medical devices.

Yoon Cheolhwan, a researcher at Korea Investment & Securities, explained, "iBeam Technology plans to increase demo products from the current six to nine in 2024 and conduct demo activities targeting about 180 customers," adding, "In the mid to long term, to strengthen marketing, the number of demo sites will be increased from the current seven to 20 by 2027."

Park Jongseon, a researcher at Eugene Investment & Securities, analyzed, "The global optical microscope market is expected to grow at a compound annual growth rate of 6.9% from 2022 to 2031," and "iBeam Technology is preparing to expand overseas entry through a global collaboration system, CRO services, and entry into the AI medical device market." He continued, "An average annual sales growth of 81.3% is expected over the next four years," emphasizing, "The freely tradable shares after listing account for 20.3% of the total shares, which is not a burdensome level."

This content was produced with the assistance of AI translation services.